Calgary’s Universal Ibogaine Inc.: A Settlement Saga
Calgary, AB – April 3, 2025 – In a recent financial update, Universal Ibogaine Inc. (IBO) disclosed some intriguing developments. The life sciences company, dedicated to delivering medicalized ibogaine-centered addiction care, announced it had reached an agreement to settle a significant debt.
The Debt Settlement
According to the press release, the debt in question amounts to $106,200, which is owed to the Company’s CEO, Nicholas Karos. The settlement will be facilitated through the issuance of common shares.
Applying for Approval from the TSXV
Universal Ibogaine is currently seeking approval from the TSX Venture Exchange (TSXV) to issue up to 4,248,000 common shares in settlement of the debt. The shares will be issued at a minimum price of $0.025 per share, although the minimum price and number of shares may vary based on TSXV requirements.
What Does This Mean for IBO Shareholders?
For existing IBO shareholders, this debt settlement could potentially result in dilution, as the issuance of new shares will increase the total number of outstanding shares. However, it is important to note that the Company is addressing a significant debt, which could contribute to its financial health and stability moving forward.
Impact on the Wider World
Beyond IBO’s shareholders, the settlement could have implications for the broader addiction care industry. If successful, this innovative approach to debt settlement could set a precedent for other companies in similar situations. It may also encourage further investment in ibogaine-based addiction treatments, as investors become more confident in the financial stability of companies in this sector.
Conclusion
Universal Ibogaine Inc.’s debt settlement marks an exciting development for the Calgary-based life sciences company. By addressing a significant financial obligation through the issuance of common shares, IBO is taking a proactive step towards financial health. For its shareholders, this may result in dilution, but it could also contribute to long-term stability. Additionally, this approach could pave the way for new precedents in the addiction care industry and encourage further investment in ibogaine-based treatments.
- Universal Ibogaine Inc. (IBO) has agreed to settle a debt of $106,200 owed to its CEO through the issuance of common shares.
- The Company is seeking approval from the TSX Venture Exchange (TSXV) to issue up to 4,248,000 common shares in settlement of the debt.
- This debt settlement could result in dilution for existing IBO shareholders but could contribute to long-term financial stability.
- The innovative approach to debt settlement could set a precedent for the addiction care industry and encourage further investment in ibogaine-based treatments.
